Summary of Perfect Diary's Conference Call Company Overview - **Company**: Perfect Diary (完美生物) - **Industry**: Beauty and Skincare Key Financial Performance - **Revenue**: In the first half of 2025, Perfect Diary achieved revenue of 6 billion CNY, a year-on-year increase of 5.21% [2] - **Net Profit**: The net profit attributable to shareholders was 1.86 billion CNY, up 5.21% year-on-year, while the net profit after deducting non-operating losses was 1.77 billion CNY, a growth of 6.64% [3] - **Gross Margin**: The gross margin stood at 74.6%, remaining stable compared to the previous year [3] - **Online vs. Offline Sales**: Online sales accounted for 88.87% of total revenue, growing 37.85% year-on-year, while offline sales declined by 7.07% [2][3] Brand Performance - **Perfect Brand**: Generated 12.5 billion CNY in revenue, a 34.36% increase, representing 70.72% of total revenue [4] - **PL Brand**: Achieved 5.16 billion CNY in revenue, up 23.87%, accounting for 29.22% of total revenue [4] - **Product Highlights**: Eye care products grew by 76.18%, skincare products by 20%, and cleansing products by 11.46% [5] Research and Development - **R&D Investment**: R&D expenses reached 40.69 million CNY, a 13.53% increase [6] - **Patents**: The company has applied for 619 patents, with 365 granted, of which 70% are invention patents [6] - **Innovation Projects**: Three new research projects were initiated, including collagen-based hydrogel development [6] Marketing and Sales Strategies - **Sales Growth**: Sales increased by 150% year-on-year, with marketing expenses decreasing by 14% [10] - **Brand Exposure**: Significant brand exposure achieved through celebrity endorsements and themed marketing campaigns, resulting in a 37% increase in search index on Douyin [11] - **Self-broadcasting Growth**: Self-broadcasting business saw explosive growth, with Q1 and Q2 increasing by 60% and 100% respectively [12] Future Outlook - **Revenue Target**: The company aims for total revenue of 21 billion CNY in 2025, a 50% increase [4] - **Profit Margin Goal**: The target profit margin for the year is set at 12% [4] - **Brand Development**: Plans to continue enhancing brand differentiation and synergy between Perfect and PL brands [9] Market Positioning - **PL Brand Transition**: PL brand has transitioned from a trendy makeup brand to a professional base makeup brand, with a growth target of 30% for the year [15][23] - **Product Series**: The main product series include the collagen series (40-50% of sales), 6D peptide series (30-35%), and anti-aging series (15-20%) [24] Challenges and Strategies - **Market Competition**: The beauty industry is facing intense competition, necessitating a focus on both profit margins and scale [21] - **Investment in Brand Building**: The company emphasizes the importance of brand building alongside immediate sales, planning to maintain brand budgets despite economic challenges [29] Conclusion - **Long-term Vision**: Perfect Diary is committed to long-term growth through innovation, brand development, and a balanced approach to profitability and scale [34]

Summary of Key Points Core Viewpoint - On August 25, a total of 33 stocks appeared on the trading leaderboard, with 17 showing net institutional buying and 16 showing net institutional selling [1]. Institutional Buying - The top three stocks with the highest net institutional buying were: - Zhaoyi Innovation: Net buying amount of 1.799 billion [1][2] - Jinli Permanent Magnet: Net buying amount of 142 million [1][2] - Robotec: Net buying amount of 140 million [1][2] - Other notable stocks with net institutional buying included: - Hengbao Co., Ltd.: Net buying amount of 120 million [2] - Yuyin Co., Ltd.: Net buying amount of 86 million [2] Institutional Selling - The top three stocks with the highest net institutional selling were: - Goldwind Technology: Net selling amount of 378 million [1][4] - Southern Precision: Net selling amount of 118 million [1][4] - Marubi Biotechnology: Net selling amount of 111 million [1][4] - Other notable stocks with net institutional selling included: - Aerospace Hongtu: Net selling amount of 847 million [3] - Guoan Da: Net selling amount of 890 million [3]

Market Overview - The Shanghai Composite Index increased by 0.82% with a trading volume of 1,639.56 million shares and a transaction amount of 26,453.26 billion yuan, representing a 31.04% increase compared to the previous trading day [1] Industry Performance - The top-performing industries included: - Non-ferrous Metals: 4.23% increase with a transaction amount of 1,480.63 billion yuan, up 55.11% from the previous day, led by Jinli Permanent Magnet with a 20.00% increase [1] - Comprehensive: 3.47% increase with a transaction amount of 46.91 billion yuan, up 32.07%, led by Zhangzhou Development with a 9.97% increase [1] - Communication: 2.98% increase with a transaction amount of 1,530.59 billion yuan, up 30.79%, led by Feiling Kesi with a 14.13% increase [1] - Real Estate: 2.62% increase with a transaction amount of 379.38 billion yuan, up 130.51%, led by Wantong Development with a 9.99% increase [1] - Steel: 2.44% increase with a transaction amount of 189.55 billion yuan, up 39.37%, led by Baosteel with a 9.93% increase [1] Underperforming Industries - The industries with the largest declines included: - Beauty and Personal Care: 0.91% decrease with a transaction amount of 75.20 billion yuan, led by Marubi Biotechnology with a 7.26% decrease [2] - Banking: 0.29% decrease with a transaction amount of 344.54 billion yuan, led by Agricultural Bank with a 1.92% decrease [2] - Textile and Apparel: 0.23% decrease with a transaction amount of 149.49 billion yuan, led by Xingye Technology with a 6.97% decrease [2]

格隆汇8月25日｜民生证券研报指出，丸美生物25H1归母净利润1.86亿元，同比+5.21%；25Q2归母净利 润5069.52万元，同比-23.08%。此外，公司每10股派发现金红利2.50元（含税），合计派发现金股利 1.00亿元，占上半年归母净利润的53.97%。分商品类型来看：上半年护肤类营收6.93亿元领跑，其次是 美容及其他/眼部/洁肤类，分别为5.18亿元/4.20亿元/1.35亿元。公司主品牌丸美聚焦大单品、势能强 劲，PL深耕底妆打造第二成长曲线，预计公司25-27年归母净利润为4.4/5.8/7.3亿元，同比增速 +27.6%/+31.8%/+27.3%，当前股价对应25-27年PE分别为42x、32x、25x，维持"推荐"评级。 ...

丸美生物今日跌6.76%，成交额4.11亿元，换手率2.44%，盘后龙虎榜数据显示，沪股通专用席位买入 1455.46万元并卖出1268.01万元，1家机构专用席位净买入580.66万元，有4家机构专用席位净卖出1.17亿 元。 ...

Core Viewpoint - Mamei Bio's net profit for H1 2025 reached 186 million yuan, a year-on-year increase of 5.21%, while Q2 net profit was 51 million yuan, reflecting a year-on-year decline of 23.08% [1] Financial Performance - H1 2025 net profit: 186 million yuan, up 5.21% year-on-year [1] - Q2 2025 net profit: 51 million yuan, down 23.08% year-on-year [1] - Proposed dividend: 2.5 yuan per share (including tax), with a dividend payout ratio of 53.97% [1] Business Strategy - The company is steadily advancing the differentiated layout and collaborative development of its dual brands, Mamei and PL Lianhuo [1] - Both brands are maintaining good development with steady market penetration [1] - Focus on a big product strategy, with classic products like "Little Gold Needle" continuing to perform well [1] Product Development - The company has a rich portfolio of collagen recombinant protein products and a complete skincare system [1] - In 2025, the investment in Shanghai Moyang Biotechnology Co., Ltd. received a Class III medical device registration certificate from the National Medical Products Administration, highlighting Mamei Bio's forward-looking market positioning [1]

Core Viewpoint - Mamei Bio achieved significant revenue growth in H1 2025, with a 30.8% year-on-year increase, and continues to expand its product line, maintaining a "buy" rating from Dongwu Securities [1][3]. Financial Performance - In H1 2025, Mamei Bio reported revenue of 1.77 billion yuan, up 30.8% year-on-year, and a net profit attributable to shareholders of 190 million yuan, up 5.2% year-on-year. The net profit after deducting non-recurring items was 180 million yuan, up 6.6% year-on-year [1]. - For Q2 2025, the company achieved revenue of 920 million yuan, a 33.5% increase year-on-year, but the net profit attributable to shareholders decreased by 23.1% to 50 million yuan, with a net profit after deducting non-recurring items of 40 million yuan, down 30.2% year-on-year [1]. - The company declared a dividend of 100 million yuan for H1 2025, with a payout ratio of 53% [1]. Profitability Metrics - The gross margin for H1 2025 was 74.6%, a slight decrease of 0.1 percentage points year-on-year, while Q2 2025 gross margin was 73.3%, down 1.5 percentage points year-on-year [1]. - The total expense ratio for H1 2025 was 61.0%, an increase of 2.5 percentage points year-on-year, primarily due to a 3.4 percentage point increase in sales expense ratio. For Q2 2025, the total expense ratio rose to 65.6%, up 3.9 percentage points year-on-year [1]. - The net profit margin for H1 2025 was 10.5%, down 2.6 percentage points year-on-year, while Q2 2025 net profit margin was 5.5%, down 4.1 percentage points year-on-year [1]. Brand Performance - Mamei and PL brands achieved strong growth in H1 2025, with revenues of 1.25 billion yuan and 520 million yuan, respectively, representing year-on-year increases of 34.4% and 23.9% [2]. - The company launched the "Super Mask" featuring advanced collagen as a key ingredient and appointed Yang Zi as its first global brand ambassador [2]. - PL brand focused on high-quality minimalist makeup, launching the "Unremovable Foundation Liquid 4.0" and appointing Li Hao as its first brand ambassador, achieving over 350 million yuan in online GMV during the 618 shopping festival [2]. Sales Channels - In H1 2025, online and offline revenues were 1.57 billion yuan and 197 million yuan, respectively, with year-on-year growth of 37.9% for online and a decline of 7.1% for offline, accounting for 88.9% and 11.1% of total revenue [2]. - The company utilized platforms like Tmall, JD, and Douyin, employing a "grass-planting to live conversion" strategy, leveraging celebrity endorsements and KOL/KOC collaborations [2]. Future Outlook - The company is expected to continue its transformation and brand focus, with strong performance anticipated from key products like the Super Mask and Unremovable Foundation Liquid [3]. - Profit forecasts for 2025-2027 are 440 million yuan, 550 million yuan, and 690 million yuan, respectively, with year-on-year growth rates of 28%, 26%, and 24% [3].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved a revenue of 1.77 billion yuan in H1 2025, representing a year-on-year increase of 30.8% [7] - The net profit attributable to shareholders for H1 2025 was 190 million yuan, up 5.2% year-on-year, while the net profit after deducting non-recurring items was 180 million yuan, an increase of 6.6% [7] - The company has a high gross margin of 74.6% in H1 2025, although the net profit margin was under pressure due to increased sales expenses [7] - The company is focusing on a big product strategy, with strong performance from key products like the "Super Mask" and "Foundation" [7] - Online sales channels showed significant growth, with online revenue reaching 1.57 billion yuan, up 37.9% year-on-year, while offline revenue decreased by 7.1% [7] Financial Projections - The company forecasts total revenue of 3.79 billion yuan for 2025, with a year-on-year growth of 27.56% [1] - The projected net profit attributable to shareholders for 2025 is 438.81 million yuan, reflecting a year-on-year increase of 28.45% [1] - The earnings per share (EPS) is expected to be 1.09 yuan for 2025, with a corresponding P/E ratio of 41.39 [1][8]

Investment Rating - The report maintains a "Recommended" rating for the company, with a current price of 45.29 yuan [4]. Core Insights - The company achieved a revenue of 1.769 billion yuan in H1 2025, representing a year-on-year growth of 30.83%. The net profit attributable to shareholders was 186 million yuan, up 5.21% year-on-year [1]. - The skincare segment led revenue growth with 693 million yuan, followed by other beauty categories [1]. - The company continues to deepen its focus on key products, achieving significant technological breakthroughs, including the launch of a new collagen mask that topped sales rankings [3]. - The PL brand also saw growth driven by enhanced product offerings and effective online marketing strategies [3]. Financial Performance - In H1 2025, the gross margin was 74.6%, with a slight decrease of 0.07 percentage points year-on-year. The net profit margin was 10.5%, down 2.56 percentage points year-on-year [2]. - The company plans to distribute a cash dividend of 2.50 yuan per 10 shares, totaling 100 million yuan, which accounts for 53.97% of the net profit for the first half of the year [1]. - Revenue projections for 2025-2027 indicate a steady growth trajectory, with net profits expected to reach 440 million yuan in 2025, 580 million yuan in 2026, and 739 million yuan in 2027 [5][7]. Product and Market Strategy - The main brand, Marubi, focuses on key products and strong brand momentum, while the PL brand is developing a second growth curve in the foundation segment [4]. - The company has launched several new products and marketing campaigns that have significantly increased engagement and sales, particularly through online platforms [3]. Future Outlook - The company is expected to maintain a robust growth rate, with projected net profit growth rates of 27.6% in 2025, 31.8% in 2026, and 27.3% in 2027 [4]. - The current price-to-earnings (PE) ratios for 2025-2027 are projected at 42x, 32x, and 25x respectively, indicating a favorable valuation trend [5][7].

Market Overview - The A-share market has shown strong performance, breaking through last year's high, with expectations for continued upward movement supported by reasonable valuations and new positive factors such as a potential interest rate cut by the Federal Reserve and a recovery in public fund issuance [2][3] - The weighted REITs index has decreased by 1.52% during the week of August 18-22, 2025, indicating a downward trend in the secondary market prices of publicly listed REITs [2] Credit Bonds - A total of 375 credit bonds were issued from August 18 to August 22, 2025, with a total issuance scale of 376.74 billion, reflecting a week-on-week increase of 12.45% [3] - The total transaction volume of credit bonds reached 1,286.40 billion, up 16.04% week-on-week, with commercial bank bonds, corporate bonds, and medium-term notes being the top three in transaction volume [3] Convertible Bonds - The CSI Convertible Bond Index increased by 2.8% during the week, with a year-to-date increase of 17.9%, slightly below the equity market performance [4] - Current valuations of convertible bonds are close to or exceed historical highs, yet the equity market remains robust, suggesting continued strong performance in the convertible bond market [4] High-end Manufacturing - Exports of engineering machinery maintained double-digit growth, with excavators, tractors, and mining machinery showing year-on-year increases of 24%, 30%, and 25% respectively [6] - The report suggests focusing on companies like QuanFeng Holdings, JuXing Technology, and Xugong Machinery due to their strong export performance [6] TMT Sector - The company SUTENG has seen rapid growth in its robotics business, indicating a successful strategic transformation [6] - The report highlights the importance of SUTENG's self-research technology and its competitive advantages in the ADAS and robotics ecosystem [6] Agriculture, Forestry, Animal Husbandry, and Fishery - The report notes a slight decline in pig prices, with the average price of live pigs at 13.75 yuan/kg, down 0.07% week-on-week [6] - The government has initiated pork storage measures to boost market sentiment, suggesting a potential recovery in pig prices [6] Medical and Biological Sector - The report recommends increasing allocations to the medical device sector, highlighting undervalued companies in Hong Kong and those with strong growth potential [7] - Companies like Weikang Medical and Mindray Medical are noted for their robust growth and research capabilities [7] Petrochemical Sector - The report indicates a significant market opportunity for the renovation of old refineries, with companies like Sinopec Engineering and PetroChina Engineering expected to benefit [7] - The report emphasizes the trend of "de-involution" in the refining industry, which may lead to a substantial market for dismantling and renovation [7] Basic Chemicals - The second phase of phosphate fertilizer export quotas has been allocated, with leading companies expected to benefit from high overseas prices [7] - The report anticipates continued high demand for high-grade phosphate rock in the short to medium term [7] Non-Banking Financials - AIA Insurance has seen new business value reach new highs, with stable growth in operating profits [10] - The report adjusts profit forecasts for AIA for 2025-2027, maintaining a "buy" rating [10] Real Estate - The property management sector shows steady growth, with a stable dividend outlook from companies like Yuexiu Services [10] - The report notes a slight decline in net profit but maintains a positive outlook due to strong project delivery from related companies [10] Electric New Energy - The report highlights the growth potential in the energy storage battery sector, with companies like Yiwei Lithium Energy expected to benefit from increased demand [24] - The company has adjusted its profit forecasts for 2025, reflecting a strong competitive position in the market [24] Textile and Apparel - The report indicates a decline in profit margins for companies like Li Ning, despite revenue growth [34] - The company is expected to maintain a strong brand presence, with a "buy" rating maintained [34]